What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?

Given the changing landscape of treatment, some patients may have already received capecitabine previously. Would this impact your treatment recommendations?

Answer from: Medical Oncologist at Academic Institution

For patients after 2 standard lines of HER2-targeted therapies with CNS progression who are not candidates for local CNS therapy, my first option would be to use trastuzumab plus tucatinib (with capecitabine if not previously used) if available (e.g. single patient IND). There is demonstrated activi...

Comments

Medical Oncologist at Northwest Georgia Oncology Centers
Thank you for your answer. Could you expand on how...

Medical Oncologist at University of Texas MD Anderson Cancer Center
The main evidence is that responses in the tucatin...

Please select the option that best describes you:

What systemic treatment would you offer for metastatic HER2+ breast cancer that has progressed through THP and TDM-1 with predominant CNS progression and without localized treatment options?

Related Questions